The early-stage trial of ABS-201, designed to treat androgenetic alopecia, showed the therapy was well tolerated with no serious adverse events reported among participants. Chief Medical Officer Ransi Somaratne noted that the emerging pharmacokinetic and immunogenicity profiles are encouraging, signaling potential for the drug to move beyond hair regrowth into other therapeutic areas such as endometriosis.

Absci plans to allocate the $100 million in proceeds to advance the clinical development of the asset. The offering, priced at $7.41 per share, drew support from a roster of financial institutions including Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile. This capital infusion follows a year of significant market performance for the company, with stock values more than doubling since January. By targeting prolactin receptors, the company aims to offer a novel approach to hair follicle regeneration for the estimated 80 million Americans affected by pattern baldness.